Lillian L. Siu

机构：University Health Network, University of Toronto, Princess Margaret Cancer Centre · ORCID：0000-0002-3500-0540

发表论文 1314 篇 · 总被引 42394 次 · h-index 102

代表论文

• Circulating tumor DNA as a biomarker in early phase clinical trials (2025 · Cancer Cell · 被引 6)
• Cancer in 2025 (2025 · Cancer Discovery · 被引 2)
• Methylation-based ctDNA monitoring in metastatic breast cancer during CDK4/6 inhibitor therapy (2026 · Nature Communications · 被引 1)
• Phase 1, multi-center clinical trial evaluating the safety, pharmacokinetics, pharmacodynamics and anti-cancer activity of PQ203, a first-in-class peptide drug conjugate targeting SORT1 in patients with advanced solid tumor malignancies (NCT07190469). (2026 · Journal of Clinical Oncology · 被引 1)
• Final analysis of the investigator-initiated randomized study of anti–PD-L1 durvalumab (durva) with radiation versus chemoradiation (CRT) for intermediate-risk HPV-positive (HPV+) locally advanced oropharyngeal squamous cell carcinoma (LA-OPSCC): Canadian Cancer Trials Group (CCTG) HN.9 (EORTC 1740-HNCG). (2026 · Journal of Clinical Oncology · 被引 1)
• Predicting immunotherapy benefit in leiomyosarcoma through active chromatin cfDNA profiling (2026 · npj Precision Oncology · 被引 1)